TRxADE HEALTH, Inc. (MEDS)
NASDAQ: MEDS · IEX Real-Time Price · USD
5.98
+0.01 (0.25%)
At close: May 1, 2024, 4:00 PM
5.88
-0.09 (-1.59%)
After-hours: May 1, 2024, 7:54 PM EDT
TRxADE HEALTH Revenue
In the year 2023, TRxADE HEALTH had annual revenue of $8.27M, a decrease of -19.30%. Revenue in the quarter ending December 31, 2023 was $2.35M with 4.26% year-over-year growth.
Revenue (ttm)
$8.27M
Revenue Growth
-19.30%
P/S Ratio
1.02
Revenue / Employee
$1,034,027
Employees
8
Market Cap
8.40M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.27M | -1.98M | -19.30% |
Dec 31, 2022 | 10.25M | 360.74K | 3.65% |
Dec 31, 2021 | 9.89M | -7.23M | -42.24% |
Dec 31, 2020 | 17.12M | 9.69M | 130.26% |
Dec 31, 2019 | 7.44M | 3.60M | 94.07% |
Dec 31, 2018 | 3.83M | 900.50K | 30.72% |
Dec 31, 2017 | 2.93M | 449.41K | 18.11% |
Dec 31, 2016 | 2.48M | -430.66K | -14.79% |
Dec 31, 2015 | 2.91M | 1.42M | 94.66% |
Dec 31, 2014 | 1.50M | 540.35K | 56.53% |
Dec 31, 2013 | 955.88K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Molecular Templates | 57.31M |
Biofrontera | 34.07M |
Universe Pharmaceuticals INC | 32.31M |
Biomerica | 5.41M |
Notable Labs | 310.00K |
BioRestorative Therapies | 145.80K |
Kazia Therapeutics | 15.65K |
MEDS News
- 8 days ago - TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K - GlobeNewsWire
- 2 months ago - TRxADE Health, Inc. Announces Special Cash Dividend - GlobeNewsWire
- 3 months ago - Trxade health, Inc files its 3Q 10Q - GlobeNewsWire
- 5 months ago - TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q. - GlobeNewsWire
- 7 months ago - TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023. - GlobeNewsWire
- 7 months ago - Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales - GlobeNewsWire
- 7 months ago - Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry. - GlobeNewsWire
- 8 months ago - TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc. - Accesswire